A Review on Prevention and Treatment of Aids

Sahoo, Chinmaya Keshari; Sahoo, Nalini Kanta; Rao, Surepalli Ram Mohan; Sudhakar, Muvvala

doi:10.15406/ppij.2017.05.00108

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final stage of AIDS where the CD4+ count declines to 200cells/µL. Out of various treatments now antiretroviral 5 therapies plays a vital role for controlling the progression of AIDS. Combination therapy is used to be the advanced care of HIV infected patients.…”

Section: Inroductionmentioning

confidence: 99%

Formulation and Evaluation of Controlled Porosity Osmotic Pump Tablets for Zidovudine and Lamivudine Combination Using Fructose as Osmogen

Sahoo

Rao

Sudhakar³

2017

J. Drug Delivery Ther.

Self Cite

View full text Add to dashboard Cite

The present study deals with the development and evaluation of controlled porosity osmotic pump (CPOP) tablets of Zidovudine-Lamivudine. Wet granulation method was used for the development of core tablets. Core tablets were incorporated with HPMCE5 LV polymer, different concentrations of fructose as osmogen and additives. The CPOP tablets were coated with cellulose acetate as a wall forming material, polyethylene glycol as flux regulating agent, and sorbitol acts as pore forming material in SPM. The formulated tablets were evaluated for FTIR, DSC, pre-compression parameters, post compression parameters, in vitro drug release study and scanning electron microscopy study. The optimized formulation had no significant effect on the p H and agitation intensity, but depends on the osmotic pressure of dissolution media indicated that mechanism of drug release. SEM images revealed that no pores were found before dissolution and after dissolution had shown the porous nature of the membrane. Short term stability study at 40±2ºC /75±5% RH for the months on the CF4 formulation indicated that there was no significant change weight variation, % friability, drug content and in vitro drug release. Cite this article as:Sahoo CK, Rao SRM, Sudhakar M, Formulation and evaluation of controlled porosity osmotic pump tablets for Zidovudine and Lamivudine combination using fructose as osmogen, Journal of Drug Delivery and Therapeutics. 2017; 7(4):41-50

show abstract

Section: Inroductionmentioning

confidence: 99%

Formulation and Evaluation of Controlled Porosity Osmotic Pump Tablets for Zidovudine and Lamivudine Combination Using Fructose as Osmogen

Sahoo

Rao

Sudhakar³

2017

J. Drug Delivery Ther.

Self Cite

View full text Add to dashboard Cite

show abstract

Development and Evaluation of Controlled Release Formulation of Lamivudine Based on Microporous Osmotic Tablet Technology Using Fructose as Osmogen

Sahoo¹,

Rao²,

Sudhakar³

2017

Indonesian J. Pharm.

Self Cite

View full text Add to dashboard Cite

The present study was undertaken to develop controlled release osmotic pump tablets of lamivudine a nucleoside reverse transcriptase inhibitor for the treatment of acquired immune deficiency syndrome (AIDS). The tablets were prepared by wet granulation method using controlled release polymer hydroxyl propyl methyl cellulose (HPMCE5 LV), MCC as a diluent, starch as binder and fructose as osmogen. The coating solution of core tablets was prepared by using cellulose acetate, poly ethylene glycol 400, 600, 4000, 6000 and acetone to a quantity sufficient with sorbitol for different batches. The prepared tablets were evaluated for pre compression parameters, post compression parameters, in vitro drug release study and scanning electron microscopy study. Among the prepared formulations LF4 batch show 97.78% drug release in 12h. The in vitro release kinetics were analyzed for different batches by different pharmacokinetic models such as zero order, first order, Higuchi, Korsmeye rPeppas and Hixon Crowell model. Short term stability study at 40±2ºC/75±5% RH for three months on the best formulation was performed showing no significant changes in thickness, hardness, friability, drug content and in vitro drug release.

show abstract

Experimental design for novel in-vitro dissolution method validation for lamivudine-150mg and zidovudine-300mg film-coated tablets

K. Aishwarya,

K. Vamshikrishna,

Mohd Omar

et al. 2023

ijamscr

View full text Add to dashboard Cite

The present study objective is Experimental Design for novel in- vitro Dissolution method validation for Lamivudine150 and Zidovudine 300 mg film-coated tablets and its provide the direction to design and conduct performance test for the same and established documentary evidence through the test method defined in the study , its helps to demonstrate that the chromatographic analytical methods for determination of dissolution in Lamivudine/Zidovudine 150 mg/300 mg film-coated tablets Films coating tablet will yield consistent, reliable and reproducible results within in the pre-determined acceptance criteria The active ingredient Lamivudine and Zidovudine and Inactive ingredients include microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, povidone, magnesium stearate, and opadry white (composed of Hydroxy Propyl methylcellulose 2910/Hypromellose 5cP, Titanium dioxide, and Polyethylene glycol 400).

show abstract

A Review on Prevention and Treatment of Aids

Cited by 3 publications

References 36 publications

Formulation and Evaluation of Controlled Porosity Osmotic Pump Tablets for Zidovudine and Lamivudine Combination Using Fructose as Osmogen

Formulation and Evaluation of Controlled Porosity Osmotic Pump Tablets for Zidovudine and Lamivudine Combination Using Fructose as Osmogen

Development and Evaluation of Controlled Release Formulation of Lamivudine Based on Microporous Osmotic Tablet Technology Using Fructose as Osmogen

Experimental design for novel in-vitro dissolution method validation for lamivudine-150mg and zidovudine-300mg film-coated tablets

Contact Info

Product

Resources

About